[Form 4] ALX Oncology Holdings Inc. Insider Trading Activity

Rhea-AI Filing Summary

Shelly Pinto, SVP Finance and CAO of ALX Oncology Holdings, Inc. (ALXO), reported a transaction on 08/15/2025. The filing shows the sale of 611 shares of the issuer's common stock at a weighted average price of $0.6404 per share, with sale prices ranging between $0.64 and $0.66. The registrant states the shares were sold to satisfy tax obligations related to the vesting of restricted stock units. Following the transaction, the reporting person beneficially owned 89,198 shares, which includes 3,000 shares acquired under the company's employee stock purchase plan on June 30, 2025. The Form 4 was signed on 08/19/2025.

Positive

• Disclosure includes explanatory notes specifying the sale was to cover tax obligations and providing the price range for the trades
• Reporting person retains meaningful ownership of 89,198 shares after the transaction
• Recent ESPP purchase disclosed: 3,000 shares acquired on June 30, 2025, included in beneficial ownership

Negative

• Disposition of 611 shares (sold) reduces insider holdings, though the filing states this was for tax obligations
• Weighted average sale price low at $0.6404 per share, reflecting the range of $0.64 to $0.66 for the sales

Insights

Securities Analyst

TL;DR: Routine tax-related sale of vested RSUs; post-transaction beneficial ownership remains material but unchanged in sign of significant disposition.

The Form 4 documents a small, specified disposition of 611 shares by an officer to cover tax obligations arising from restricted stock unit vesting. The weighted average sale price is disclosed as $0.6404, and the filer offers to provide per-trade detail on request. The report also discloses retention of 89,198 shares after the sale and a recent ESPP purchase of 3,000 shares on June 30, 2025. This appears to be an administrative liquidity action rather than a strategic divestiture; the filing includes appropriate explanations and the requisite signature.

Corporate Governance Expert

TL;DR: Disclosure is complete for the reported transaction and includes required explanatory notes.

The Form 4 identifies the reporting person, relationship to the issuer (Officer: SVP, Finance and CAO), transaction date, transaction code indicating a sale to satisfy tax obligations, and post-transaction beneficial ownership. The explanation clarifies multiple trade prices and offers supplemental details on request, which supports transparency and compliance with Section 16 reporting expectations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pinto Shelly

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, FINANCE AND CAO

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		S(1)		611	D	$0.6404(2)	89,198(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.64 to $0.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2025.

	/s/ Shelly Pinto	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Shelly Pinto report on Form 4 for ALXO?

The Form 4 reports the sale of 611 shares on 08/15/2025.

Why were the shares sold according to the filing?

The filing states the shares were sold to satisfy tax obligations in connection with the vesting of restricted stock units.

What price did the shares sell for in the Form 4?

The weighted average sale price was reported as $0.6404 per share; individual sale prices ranged from $0.64 to $0.66.

How many ALXO shares does the reporting person beneficially own after the transaction?

The reporting person beneficially owned 89,198 shares following the reported transaction.

Does the filing disclose any recent employee stock purchases?

Yes. The filing discloses 3,000 shares acquired under the issuer's employee stock purchase plan on June 30, 2025.